AB0912 Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial

Christopher Em Griffiths; Kim Papp; Alexa B. Kimball; B. Randazzo; Yasmine Wasfi; S. Li; Yaung‐Kaung Shen; Andrew Blauvelt

doi:10.1136/annrheumdis-2018-eular.5825

Related publications

Article2018

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Christopher Em Griffiths, Kim Papp, Alexa B. Kimball, B. Randazzo, Michael Song, Shu Li, Yaung‐Kaung Shen, Andrew Blauvelt

Letter2023

Immunogenicity and pharmacokinetics of guselkumab among patients with moderate‐to‐severe psoriasis in VOYAGE‐1 and VOYAGE‐2

April W. Armstrong, Kilian Eyerich, Curdin Conrad, Yihong Zhu, Ya‐Wen Yang, Megan Miller, Yin You, Yaung‐Kaung Shen, Peter Foley, Christopher Em Griffiths, Bruce Strober

Article2018

Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis

Christopher Em Griffiths, KA Papp, Michael Song, B. Randazzo, S Li, Y-K Shen, Chenglong Han, Andrew Blauvelt

Article2017

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase <scp>III VOYAGE</scp> 1 and <scp>VOYAGE</scp> 2 studies

Kenneth B. Gordon, Andrew Blauvelt, Peter Foley, Michael Song, Yasmine Wasfi, B. Randazzo, Yaung‐Kaung Shen, Yin You, Christopher Em Griffiths

Article2020

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1

Christopher Em Griffiths, Kim Papp, Michael Song, Megan Miller, Yin You, Yaung‐Kaung Shen, Chenglong Han, Andrew Blauvelt

AB0912 Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial

Discussion(0)